Citius Oncology Inc.
XNAS:CTOR 3:10:18 PM EDT
| Market Cap (Intraday) | 82.56M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 8.9 |
| 10-Day MA | $0.98 |
| 50-Day MA | $0.83 |
| 200-Day MA | $0.88 |
Citius Oncology Inc. Stock, XNAS:CTOR
11 Commerce Drive, 1st floor, Cranford, New Jersey 07016
United States of America
Phone:
Number of Employees:
Description
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.